Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when LAB files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Delisting (new) — Company received formal Nasdaq notice of non-compliance with minimum bid price requirement, triggering potential delisting process.
Standard BioTools receives Nasdaq delisting warning over $1 minimum stock price violation
Filed April 24, 2026 · Period ending September 13, 2025 · ~1 min read
Key Changes
-
high
Nasdaq notified Standard BioTools on April 20, 2026 that its stock failed to maintain the required $1.00 minimum bid price for 30 consecutive days, triggering a formal deficiency notice under listing rules.
Item 3.01 verify on EDGAR → -
high
Company has until October 19, 2026 (180 days) to regain compliance by closing at $1.00 or above for 10 consecutive trading days, or face potential delisting from Nasdaq Global Select Market.
Item 3.01 verify on EDGAR → -
high
If the company fails to meet the deadline, it may transfer to Nasdaq Capital Market for an additional 180 days or implement a reverse stock split to boost share price and regain compliance.
Item 3.01 verify on EDGAR → -
medium
The stock continues trading normally under ticker LAB during the compliance period, with no immediate impact on business operations or SEC reporting requirements.
Item 3.01 verify on EDGAR → -
high
Management acknowledged no guarantee exists that the company will successfully regain compliance or receive additional extensions from Nasdaq if needed.
Item 3.01 verify on EDGAR →
Summary
Standard BioTools disclosed it received a deficiency notice from Nasdaq on April 20, 2026 for failing to maintain the exchange's $1.00 minimum bid price requirement. The company's stock closed below this threshold for 30 consecutive business days, violating Nasdaq Global Select Market listing rules.
While the shares continue trading normally under ticker LAB, the company now faces a critical 180-day deadline to restore compliance. For retail investors, this represents a significant warning sign about the stock's recent performance and future listing status.
A delisting would force shares to trade on less liquid over-the-counter markets, potentially making it harder to buy or sell positions and reducing institutional ownership. The company has options including a reverse stock split to artificially boost the share price, though management provided no assurance of success. Investors should monitor the stock's daily closing price through October 2026. Watch for any announcements about reverse stock splits or strategic changes aimed at boosting the share price, and track whether the company achieves 10 consecutive closes above $1.00 before the deadline expires.
Section-by-Section Diff
Event · Item 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule
Item 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On April 20, 2026, Standard BioTools Inc. (NASDAQ: LAB) (the “Company”) received a notification letter (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (the “Nasdaq”) indicating that the Company did not meet the minimum bid price requirement set forth in Nasdaq’s Listing Rules for continued listing on The Nasdaq Global Select Market. The Notice follows a 30-day period during which the Company’s share price closed below the $1.00 threshold established under Nasdaq Listing Rule 5450(a) (1) (the “Minimum Bid Price Requirement”).
Standard BioTools received a deficiency notice from Nasdaq on April 20, 2026 because its stock price closed below $1.00 per share for 30 consecutive business days. This violates Nasdaq's minimum bid price requirement for continued listing on The Nasdaq Global Select Market. The stock continues to trade normally under ticker LAB while the company works to regain compliance.
Added in current filing · verify on EDGAR →
The Company now has a period of 180 calendar days from the date of the Notice, or until October 19, 2026, to regain compliance with the Minimum Bid Price Requirement for a minimum of 10 consecutive business days.
The company has until October 19, 2026 (180 days from the notice date) to achieve a closing bid price of at least $1.00 for 10 consecutive business days. If unsuccessful, the company may qualify for an additional 180-day extension by transferring to The Nasdaq Capital Market and potentially implementing a reverse stock split.
Added in current filing · verify on EDGAR →
The Notice has no immediate effect on the listing or trading of the Company’s common stock on The Nasdaq Global Select Market, which will continue to trade uninterrupted on Nasdaq under the ticker “LAB”. The Notice also does not affect the ongoing business operations of the Company or its reporting requirements with the Securities and Exchange Commission.
The deficiency notice does not immediately delist the stock or halt trading. Shares continue trading normally on Nasdaq under ticker LAB, and the company's business operations and SEC reporting obligations remain unchanged during the compliance period.
Added in current filing · verify on EDGAR →
The Company intends to work toward restoring compliance within the prescribed timeframe. However, there can be no assurance that the Company will be able to regain compliance with the Minimum Bid Price Requirement or that the Staff will grant the Company a further extension of time to regain compliance, if applicable.
While the company states its intention to regain compliance, it explicitly acknowledges there is no guarantee it will successfully restore the minimum bid price or receive additional extensions from Nasdaq if needed. This creates uncertainty about the stock's future listing status.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 2, 2026 · How we verify